Common Sense Oncology shared on LinkedIn:
“In this episode of the Common Sense Oncology podcast, doctors Brooke Wilson, Chris Booth, Haydeé Verduzco, and patient advocate Carolyn Taylor discuss the new breakthrough pancreatic cancer drug Daraxonrasib, and what its price tag of $40,000 USD per month, or $56,300 CAD per month, means for patients in North America and across the globe.”
Listen on your favourite platform:
Spotify:
Apple:
Daraxonrasib in Metastatic Pancreatic Cancer, Findings of Phase III RASolute 302 trial
- Improved overall survival: In the Phase III RASolute 302 trial, daraxonrasib improved median overall survival compared with chemotherapy in previously treated metastatic pancreatic cancer (13.2 vs. 6.7 months; HR 0.40).
- Potential benefit across RAS subgroups: Survival outcomes favored daraxonrasib across several RAS mutation subgroups, including G12D (HR 0.49) and G12V (HR 0.32), suggesting activity across different molecular profiles.
- Consistent efficacy: Daraxonrasib showed favorable survival outcomes across different previous treatment backgrounds, including gemcitabine/nab-paclitaxel, modified FOLFIRINOX/FOLFOX, and liposomal irinotecan-based regimens.
- Limitations: Some mutation-defined subgroups were small, with confidence intervals crossing 1, limiting the certainty of subgroup-specific benefits. The relatively short median follow-up of 8.5 months also leaves long-term outcomes uncertain.
You may also be interested in:
Common Sense Oncology Brings Patients Perspectives to Kenya’s Cancer Conference
